Table 1.
Data is displayed as median, 25%, and 75% percentiles. Numeric data is displayed as number of participants (n) and percentage (%) where appropriate (sums do not add up to 100% due to rounding).
| CKD (n = 160) | HD (n = 206) | KTR (n = 216) | |
|---|---|---|---|
| Age (years) | 63.1 (53.5–74.5) | 69.5 (57.5–78.6) | 59.9 (50.7–68.5) |
| Female (n, %) | 66 (41) | 66 (32) | 69 (32) |
| BMI (kg/m2) | 25.6 (23.3–29.3) | 24.9 (22.2–28.4) | 24.8 (21.7–27.8) |
| Primary renal disease (n, %) | |||
| Diabetic nephropathy | 14 (9) | 45 (22) | 28 (13) |
| Glomerulonephritis | 64 (40) | 35 (17) | 71 (33) |
| Other | 49 (31) | 55 (27) | 77 (36) |
| Unknown | 3 (2) | 23 (11) | 11 (5) |
| Vascular nephropathy | 30 (19) | 48 (23) | 29 (13) |
| Comorbidities (n) | |||
| Cardiovascular disease | 45 | 98 | 92 |
| Cerebrovascular disease | 16 | 33 | 34 |
| Active or former malignancy | 13 | 35 | 53 |
| Diabetes mellitus | 36 | 77 | 79 |
| Comedication (n, %) | |||
| Treatment with RAAS inhibitors | 83 (52) | 62 (30) | 93 (43) |
| High-dose glucocorticoid treatment during last year (≥1 mg/kg) | 6 (4) | 4 (2) | 16 (7) |
| Tacrolimus | - | 7 (3) | 152 (70) |
| Cyclosporine A | - | 1 (0.5) | 38 (18) |
| Azathioprine | - | 0 | 33 (15) |
| Mycophenolic acid | - | 2 (1) | 148 (69) |
| Belatacept | - | 0 | 14 (6) |
| Glucocorticoids | - | 8 (4) | 178 (82) |
| mTor inhibitors | - | 0 | 11 (5) |
| Rituximab | 30 (19) | - | - |
| Time between 1st vaccination and rituximab (days) | 242 (127–324) | 2 (1–4) | 2 (1–3) |
| Classes of antihypertensive drugs (n) | 2 (1–3) | ||
| Laboratory values | |||
| Albumin (g/dL) | 4.0 (3.7–4.3) | 3.8 (3.4–4.1) | |
| Hemoglobin (g/dL) | 132 (117–141) | 111 (105–120) | 4.1 (3.9–4.4) |
| C-reactive protein (mg/dL) | 0.20 (0.09–0.46) | 0.33 (0.16–0.95) | 134 (122–146) |
| eGFR (mL/min/1.73 m2) | 29.9 (19.8–49.9) | - | 0.19 (0.08–0.40) |